Get the Stockscreener App
0.90
1.12%
0.01
After Hours:
.92
0.02
+2.22%
Jaguar Health Inc stock is traded at $0.90, with a volume of 153.54K.
It is up +1.12% in the last 24 hours and down -11.76% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$0.89
Open:
$0.899
24h Volume:
153.54K
Relative Volume:
0.36
Market Cap:
$10.62M
Revenue:
$10.48M
Net Income/Loss:
$-37.74M
P/E Ratio:
-0.0556
EPS:
-16.1846
Net Cash Flow:
$-29.03M
1W Performance:
+9.36%
1M Performance:
-11.76%
6M Performance:
-22.41%
1Y Performance:
-86.36%
1-Day Range:
$0.87
$0.9182
1-Week Range:
$0.83
$0.97
52-Week Range:
$0.7786
$21.60
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
0.90 | 10.62M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO - Corsicana Daily Sun
This Drug Could Fix The Biggest Problem With Ozempic and Wegovy - StockTitan
Jaguar Health Stock Hits 52-Week Low at $0.81 Amid Challenges - MSN
Jaguar Health Stock Hits 52-Week Low at $0.81 Amid Challenges By Investing.com - Investing.com South Africa
Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025 - Yahoo Finance
Jaguar Health stock hits 52-week low at $0.84 amid challenges - Investing.com Australia
Jaguar Health Awards Strategic RSU Grants to Key New Employees in Retention Push - StockTitan
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Hastings Tribune
Botanical and Plant-Derived Drugs Market to Grow by USD 18.66 Billion (2025-2029), Driven by Government Initiatives and AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase - AccessWire
Jaguar Health CEO to Present at Two Major Healthcare Investor Events in January 2025 - StockTitan
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum - Joplin Globe
Magdalena Biosciences to Submit Groundbreaking IND for First-Ever Schizophrenia Cognitive Treatment - StockTitan
Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2024 Earnings Call Transcript - MSN
FDA approves orphan-drug designation for Jaguar Health’s cholera drug, Crofelemer - MSN
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications - Barchart
Jaguar Health's Magdalena JV Imports 6kg of Coca Leaf for Novel Mental Health Drug Development - StockTitan
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder - Corsicana Daily Sun
Jaguar Health Launches Phase 2 Trial for Rare Pediatric Disease Treatment with Orphan Drug Status - StockTitan
FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera - Eagle-Tribune
Jaguar Health Secures FDA Orphan Drug Status for Groundbreaking Cholera Treatment - StockTitan
Jaguar Health stock plunges to 52-week low of $0.87 By Investing.com - Investing.com Canada
Jaguar Health stock plunges to 52-week low of $0.87 - Investing.com
FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES - Quantisnow
Jaguar Health Advances 5 Clinical Trials for Rare Disease Drug Crofelemer, Unveils Development Roadmap - StockTitan
Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer - Yahoo Finance
JAGXJaguar Health, Inc. Latest Stock News & Market Updates - StockTitan
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS) - AccessWire
Jaguar Health's Phase 3 Trial Shows Breakthrough Results for Cancer Therapy Diarrhea Treatment - StockTitan
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS) - Corsicana Daily Sun
Jaguar Health to Present Promising Breast Cancer Treatment Data at Major Symposium - StockTitan
Jaguar Health Launches Major Clinical Trial for Orphan Drug Crofelemer in Short Bowel Syndrome - StockTitan
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins - Yahoo Finance
Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine - Corsicana Daily Sun
Botanical and Plant-Derived Drugs Market to grow by USD 20.93 Billion (2024-2028), driven by government initiatives, with AI powering market evolutionTechnavio - The Malaysian Reserve
Jaguar Health Targets 6M Annual Cases With Novel Dog Diarrhea Drug NP300 - StockTitan
Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs - Yahoo Finance
Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference - AccessWire
Jaguar Health CEO to Present at NobleCon20 and Emerging Growth Conference | JAGX Stock News - StockTitan
Jaguar Health seeking partner to develop, commercialize NP300 - TipRanks
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs - WSIL TV
Jaguar Health Seeks Partner for Novel Dog Diarrhea Drug Targeting 6M Annual Cases | JAGX Stock News - StockTitan
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the YearEurope” - AccessWire
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):